NCT04061850View on ClinicalTrials.gov

Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

88

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

August 31, 2020

Conditions
Mantle Cell Lymphoma
Trial Locations (1)

06351

81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT04061850 - Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter